Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 6/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22752635 | 1.00 | DHFR (0.35) | DHFRPKMTSHRCNR1CNR2 | |
| SCHEMBL19252971 | 1.00 | DHFR (0.35) | DHFRPKMTSHRCNR1CNR2 | |
| SCHEMBL22778534 | 1.00 | DHFR (0.35) | DHFRPKMTSHRCNR1CNR2 | |
| SCHEMBL19251374 | 0.85 | CNR2 (0.33) | TSHRCNR1CNR2KDM4E | |
| SCHEMBL22752366 | 0.85 | CNR2 (0.33) | TSHRCNR1CNR2KDM4E | |
| SCHEMBL22778499 | 0.85 | CNR2 (0.33) | TSHRCNR1CNR2KDM4E | |
| SCHEMBL19251172 | 0.84 | CNR2 (0.32) | TSHRCNR1CNR2KDM4E | |
| SCHEMBL19251313 | 0.83 | CNR2 (0.31) | CNR1CNR2 | |
| SCHEMBL19184855 | 0.83 | KDM4E (0.37) | TSHRCNR1CNR2KDM4ENPC1 | |
| SCHEMBL22752329 | 0.83 | CNR2 (0.32) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858360-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-08 | — | — | US | disclosed |
| US-9732083-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858360-B2 | Tricyclic gyrase inhibitors | TOP1, TOP2A, TOP2B | DHFR 51/4885PKM 1502/4885TSHR 4555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.